Ampio Pharmaceuticals, Inc. today announced the completion of patient enrollment in a dose-escalation run-in study to a Phase III pivotal trial evaluating Ampion in the treatment of moderate to severe osteoarthritis of the knee.

View article:
Ampio completes patient enrollment in dose-escalation run-in study of Ampion for treatment of knee osteoarthritis

Scroll to Top